This session explores how targeted, biology-aware Artificial Intelligence (AI) is being used to understand and fix toxicity issues in failed drugs—reviving assets from biotech pipelines and turning them into valuable opportunities. By identifying which compounds can be rescued and repositioned, AI is unlocking differentiated deal flow and delivering real value to partners and investors.
• Discover how AI is proactively sourcing assets—creating data-driven, de-risked deal flow. • Learn how AI can help fix toxicity issues to reposition high-potential but previously failed drugs. • Cut through the noise: what BD&L teams and investors should really look for in AI platforms.
